Home›Screener›BTAI›Profile
D
38/100

BioXcel Therapeutics

BTAINeuroscience
← Signals View
📋
Analyst Summary
✓ VERIFIED2026-04-11

BioXcel Therapeutics (BTAI) is the lead sponsor of 1 active clinical trials listed on ClinicalTrials.gov[2], including 1 Phase 1[1].

BTAI has 4 Form 4 insider filings recorded at the SEC in the past 30 days[3].

Sources

  1. ClinicalTrials.gov (2026-04-11) ↗
  2. ClinicalTrials.gov (2026-04-11) ↗
  3. SEC EDGAR · 0001720893 (2026-04-11) ↗
🔬
Clinical Trials
1
NCT05025605Schizophrenia, Schizo-Affective Disorder, Schizophreniform; Schizophrenic, Bipolar Disorder I, Bipolar Disorder II
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
👤
Insider Activity
1
4 filings
Source ↗
sec_edgar · Retrieved 2026-04-11
Not financial advice. BiotechSigns profiles are AI-generated from verified public sources (ClinicalTrials.gov, SEC EDGAR) and are for informational purposes only. Always do your own due diligence before making investment decisions.
Score Breakdown
Score Trend
2026-04-132026-06-02
Signal Summary
PDUFA Dates0
Insider Filings1
Clinical Trials1
Sector Peers (Neuroscience)
SAVACassava Sciences
A
HRMYHarmony Biosciences
A
DNLIDenali Therapeutics
C
SAGESage Therapeutics
C
NBIXNeurocrine Biosciences
D
Data Provenance
cik1 verified
clinical trial1 verified
insider buy1 verified
trial count2 verified
Every claim backed by source URL from ClinicalTrials.gov or SEC EDGAR